Indivior PLC
INDV.L- Latest Trade
- trading higher1,681GBp
- 0
- 0.00%
- As of Jun 7 2023. Values delayed up to 15 minutes
- Today's Range
- -- - --
- 52 Week Range
- 1,330.00 - 2,020.00
- Previous Close
- 1,681.00
- Open
- 0.00
- Volume
- 0.00
- 3 Month Average Trading Volume
- 7.61
- Shares Out (Mil)
- 137.88
- Market Cap
- 2,194.21
- Forward P/E
- 17.10
- Dividend Yield
- 0.00
Key Statistics
1.50 mean rating - 4 analysts
- P/E Excl. Extra Items (TTM)
- 0.00
- Price To Sales (TTM)
- 2.88
- Price To Book (Quarterly)
- 37.90
- Price To Cash Flow (Per Share TTM)
- 0.00
- Total Debt/Total Equity (Quarterly)
- 387.50
- Long Term Debt/Equity (Quarterly)
- 372.22
- Return On Investment (TTM)
- -5.85
- Return On Equity (TTM)
- -2.87
2021 (millions USD)
About Indivior PLC (INDV.L)
Company Information
Indivior PLC is a pharmaceutical company. The Company develops medicines to treat addiction and serious mental illnesses. The Company focuses on building a portfolio of opioid dependence treatments. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Its product pipeline focuses on development and discovery of non-opioid treatment strategies for opioid use disorder (OUD), as well as therapies to address the needs of people suffering from alcohol, stimulant, and cannabis use disorders. Its SUBLOCADE, SUBUTEX and SUBOXONE are used for the treatment of opioid use disorder (OUD). Its PERSERIS is used for the treatment of Schizophrenia. The Company's pipeline products include AEF0117, INDV-2000, INDV-1000, RBP-6000, RBP-7000, Buprenorphine/ Naloxone Sublingual Film, Buprenorphine/ Naloxone Sublingual Tablet, and Buprenorphine Sublingual Tablet, OPNT003, OPNT002, and OPNT004.
Address
234 Bath RoadSLOUGH,
SL1 4EE
United Kingdom
Industry
Biotechnology & Drugs
Executive Leadership
- Graham Hetherington
- Non-Executive Independent Chairman of the Board
- Mark Crossley
- Chief Executive Officer, Executive Director
- Ryan Preblick
- Chief Financial Officer, Executive Director
- Jon Fogle
- Chief Human Resource Officer
- Christian Heidbreder
- Chief Scientific Officer
- Cynthia Cetani
- Chief Integrity and Compliance Officer
- Jeffrey W. Burris
- Chief Legal Officer
- Nina Delorenzo
- Chief Global Impact Officer
- Richard Simkin
- Chief Commercial Officer
- Hillel West
- Chief Manufacturing and Supply Officer
- Kathryn Barbara Hudson
- Company Secretary
- Jerome J. Lande
- Non-Executive Director
- Peter Bains
- Non-Executive Independent Director
- Joanna Le Couilliard
- Non-Executive Independent Director
- A. Thomas Mclellan
- Non-Executive Independent Director
- Lorna Parker
- Non-Executive Independent Director
- Daniel J. Phelan
- Senior Non-Executive Independent Director
- Barbara A. Ryan
- Independent Non-Executive Director
- Mark P. Stejbach
- Non-Executive Independent Director
- Juliet Thompson
- Non-Executive Independent Director
Latest News
- BusinessIndivior lowers profit outlook on Opiant deal costs, boosts sales view
Indivior Plc raised its revenue forecast for fiscal 2023, but lowered its profit expectations due to operating expenses associated with its buyout of Opiant Pharmaceuticals last month.
Financials
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,959.00 | 0.33% |
| Copper | 720.45 | 0.28% |
| Brent Crude Oil | 75.72 | 0.75% |
| CBOT Soybeans | 1,350.25 | 0.22% |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,283.85 | 0.24% |
| Euro STOXX 50 | 4,295.22 | -- |
| FTSE 100 | 7,628.10 | 0.37% |
| Nikkei 225 | 31,913.74 | 1.82% |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes